

New preclinical data on MIV-818 accepted for presentation at EASL's HCC Summit in March

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new preclinical data for MIV-818 will be presented at the HCC Summit 2018, organized by the European Association for the Study of the Liver (EASL), on 1-3 March 2018. MIV-818 is Medivir's proprietary nucleotide prodrug that is being developed for the treatment of hepatocellular carcinoma and other liver cancers. Two presentations will be made at the conference, covering the preclinical efficacy and pharmacokinetic profile of MIV-818.

The abstracts accepted for presentation at the HCC Summit 2018 are as follows:

Abstract P01-05

The biomarker potential of Ki67 and pH2AX immunohistochemistry in guiding use of the liver-targeting nucleotide MIV-818 in patients with hepatocellular carcinoma

Mark Albertella, Biljana Rizoska, Misti McCain, Calum Kirk, Fredrik Öberg, Richard Bethell and Helen Reeves.

Abstract P02-04

Liver targeting and anti-tumor efficacy of the nucleotide prodrug MIV-818 in nonclinical models of hepatocellular carcinoma

Biljana Rizoska, Johan Bylund, Karin Tunblad, Rodrigo Palma Villar, Alastair Kyle, Andrew Minchinton, Richard Bethell, Karin Göhlin and Mark Albertella.

Details of all presentations for the HCC Summit 2018 are available at the conference website:

<http://www.easl.eu/hcc2018/>

For further information, please contact:

Erik Björk, CFO, Medivir AB, mobile: +46 (0)72 228 2831

Richard Bethell, CSO, Medivir AB, mobile: +46 72 704 3211

About Medivir

Medivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Medivir is listed on the Nasdaq Stockholm Mid Cap List.